Sorrento Therapeutics Inc
NASDAQ:SRNE
Intrinsic Value
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of SRNE.
Sorrento Therapeutics Inc's market capitalization is 156.8m USD.
SRNE stock price is 0.3322 USD.
SRNE.
SRNE. Open DCF Valuation
SRNE. Open Relative Valuation
SRNE.
SRNE's Revenue has grown by 19% over the past 12 months.
SRNE's long-term liabilties (662m USD) exceed its long-term assets (457m USD).
SRNE has negative Operating Income for the last twelve months.
SRNE has negative Net Income for the last twelve months.
SRNE's ROE (Return on Equity) for the past 12 months is very high and is equal to 3 079%.
SRNE's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -84%.
SRNE's short-term liabilties (265m USD) exceed its short-term assets (133m USD).
SRNE has positive Gross Profit for the last twelve months.
SRNE has negative Free Cash Flow for the last twelve months.
SRNE has negative Net Debt. This means that the company has more cash and short-term investments (81m USD) than debt (22m USD).
SRNE has very high three-year average ROE (Return on Equity): 1 026%. The company is very efficient at transforming stockholders' equity into net income.
SRNE has negative three-year average ROIC (Return on Invested Capital): -28%. The company is not efficient at using invested capital to generate operating income.
SRNE's D/E (Debt to Equity) is very low and is equal to -1.03.
SRNE's Altman Z-Score is very low and is equal to -8.07.
SRNE doesn't generate enough operating income (-315m USD) to safely cover interest payments on its debt (1m USD).
Fundamental Analysis
Sorrento Therapeutics Inc
Balance Sheet Decomposition
Sorrento Therapeutics Inc
| Current Assets | 96.4m |
| Cash & Short-Term Investments | 50m |
| Receivables | 24.5m |
| Other Current Assets | 21.9m |
| Non-Current Assets | 376.5m |
| Long-Term Investments | 17.2m |
| PP&E | 138.4m |
| Intangibles | 217.2m |
| Other Non-Current Assets | 3.7m |
| Current Liabilities | 327.9m |
| Accounts Payable | 47.5m |
| Accrued Liabilities | 255.3m |
| Other Current Liabilities | 25.1m |
| Non-Current Liabilities | 163.5m |
| Long-Term Debt | 19.1m |
| Other Non-Current Liabilities | 144.4m |
Earnings Waterfall
Sorrento Therapeutics Inc
|
Revenue
|
62.8m
USD
|
|
Cost of Revenue
|
-33.5m
USD
|
|
Gross Profit
|
29.4m
USD
|
|
Operating Expenses
|
-344.8m
USD
|
|
Operating Income
|
-315.4m
USD
|
|
Other Expenses
|
-257.5m
USD
|
|
Net Income
|
-572.8m
USD
|
Free Cash Flow Analysis
Sorrento Therapeutics Inc
What is Free Cash Flow?
SRNE Profitability Score
Profitability Due Diligence
Sorrento Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
Score
Sorrento Therapeutics Inc's profitability score is 44/100. The higher the profitability score, the more profitable the company is.
SRNE Solvency Score
Solvency Due Diligence
Sorrento Therapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Score
Sorrento Therapeutics Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SRNE Price Targets Summary
Sorrento Therapeutics Inc
Ownership
SRNE Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
SRNE Price
Sorrento Therapeutics Inc
| Average Annual Return | 20.45% |
| Standard Deviation of Annual Returns | 76.62% |
| Max Drawdown | -99% |
| Market Capitalization | 156.8m USD |
| Shares Outstanding | 471 880 000 |
| Percentage of Shares Shorted | 11.89% |
SRNE News
Last Important Events
Sorrento Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Sorrento Therapeutics Inc
Company Profile
Sorrento Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 799 full-time employees. The company went IPO on 2007-01-19. The firm's segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. Sorrento's immuno-oncology platforms include key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS; and diagnostic test solutions, including COVITRACK and COVISTIX.
You don't have any saved screeners yet
